OPKO Health (OPK) to Release Earnings on Thursday
OPKO Health (NASDAQ:OPK) is set to release its quarterly earnings on February 27, with analysts predicting earnings of ($0.08) per share and revenue of $155.42 million. The stock is currently trading at $1.72, with a 12-month range of $0.86 to $1.76. Recent analyst ratings include a "buy" from HC Wainwright with a $3.00 target and a downgrade to "sell" from StockNews.com. CEO Phillip Frost recently purchased 199,072 shares, increasing insider ownership to 47.26%.
OPKO Health (NASDAQ:OPK - Get Free Report) is anticipated to post its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect OPKO Health to post earnings of ($0.08) per share and revenue of $155.42 million for the quarter. Investors interested in participating in the company's conference call can do so using this link.
OPKO Health Trading Up 2.4 %
- 3 Stocks That Wall Street Insiders Can’t Stop Buying
Shares of OPKO Health stock opened at $1.72 on Tuesday. OPKO Health has a 12-month low of $0.86 and a 12-month high of $1.76. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -9.05 and a beta of 1.63. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The company's 50-day moving average price is $1.54 and its 200-day moving average price is $1.55.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on OPK shares. HC Wainwright reissued a "buy" rating and issued a $3.00 price target on shares of OPKO Health in a report on Wednesday, January 8th. Barrington Research reissued an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th. Finally, StockNews.com downgraded shares of OPKO Health from a "hold" rating to a "sell" rating in a report on Wednesday, January 15th.
- MarketBeat Week in Review – 7/17 - 7/21
View Our Latest Report on OPKO Health
Insider Activity at OPKO Health
In related news, CEO Phillip Md Et Al Frost bought 199,072 shares of the stock in a transaction that occurred on Friday, November 29th. The shares were acquired at an average cost of $1.53 per share, with a total value of $304,580.16. Following the completion of the purchase, the chief executive officer now directly owns 211,911,477 shares of the company's stock, valued at $324,224,559.81. This trade represents a 0.09 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have purchased 1,521,609 shares of company stock valued at $2,313,710 over the last three months. 47.26% of the stock is owned by corporate insiders.
OPKO Health Company Profile
(Get Free Report)- OPKO Health is the Little Giant of Diversified Healthcare
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
See Also
- Five stocks we like better than OPKO Health
- How to Start Investing in Real Estate
- Finding Hidden Gems: Unconventional Penny Stock Investing
- What Does Downgrade Mean in Investing?
- Price Targets on NVIDIA Rise in Front of Earnings
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in OPKO Health Right Now?
Before you consider OPKO Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OPKO Health wasn't on the list.
While OPKO Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
